scholarly journals Nutritional Management of a Patient with a High-Output Stoma after Extensive Small Bowel Resection to Treat Crohn's Disease

2019 ◽  
Vol 8 (3) ◽  
pp. 247 ◽  
Author(s):  
Yun Jung Lee ◽  
MeeRa Kweon ◽  
Misun Park
2021 ◽  
Vol 8 ◽  
Author(s):  
Claudia Seifarth ◽  
Leonard N. Augustin ◽  
Kai S. Lehmann ◽  
Andrea Stroux ◽  
Johannes C. Lauscher ◽  
...  

Background: Ileostomy is often required in patients undergoing bowel resections for inflammatory bowel diseases (IBD), colorectal cancer, and emergencies. Unfortunately, some patients develop a high-output stoma (HOS). This condition affects homeostasis and may be life threatening. We aimed to identify possible risk factors for the development of HOS.Patients and methods: From 2012 to 2018, 296 patients who underwent ileostomy at Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin were retrospectively analyzed. Emergency operations were included. Diverting ileostomy, end ileostomies and anastomotic stomata with at least part ileum, were examined. HOS was defined as stoma output of more than 1,000 mL per day for more than 3 days. Univariate and multivariable analyses were used to detect potential risk factors for the development of HOS.Results: 41 of 296 patients developed HOS (13.9%). Mortality was 0.3%. In the univariate analysis, age (p < 0.002), diagnosis (Crohn's disease, p = 0.005), arterial hypertension (p = 0.023), surgical procedure (right-sided colectomy, small bowel resection, p < 0.001), open technique (p < 0.002), emergencies (p = 0.014), and anastomotic ileostomy (p < 0.001) were identified as risk factors. In the multivariable logistic regression, older age, diagnosis (Crohn's disease) and surgical procedure (right-sided colectomy, separate ileostomy, small bowel resection) remained significant risk factors.Conclusion: The occurrence of HOS is a relevant problem after ileostomy. The identification of risk factors for a high-output may be helpful for monitoring, early diagnosis and initiation of therapy as well as in the planning of close follow-up care.


1984 ◽  
Vol 19 (5) ◽  
pp. 691-696 ◽  
Author(s):  
I. Hessov ◽  
L. Mosekilde ◽  
F. Melsen ◽  
S. Fasth ◽  
L. Hultén ◽  
...  

2009 ◽  
Vol 69 (5) ◽  
pp. AB199-AB200
Author(s):  
Osamu Watanabe ◽  
Takafumi Ando ◽  
Kazuhiro Ishiguro ◽  
Nobuyuki Miyake ◽  
Motofusa Hasegawa ◽  
...  

2009 ◽  
Vol 207 (1-6) ◽  
pp. 119-122 ◽  
Author(s):  
Andreas Aly ◽  
Franz Bárány ◽  
Bo Kollberg ◽  
Ulla Monsén ◽  
Olof Wisén ◽  
...  

1996 ◽  
Vol 10 (5) ◽  
pp. 317-321
Author(s):  
Neena S Abraham ◽  
Richard N Fedorak

Osteoporosis has long been a recognized complication of Crohn’s disease (CD), with a documented incidence ranging from 31% to 65%. The cause of osteoporosis in Crohn’s patients is likely multifactorial; corticosteroids, inflammatory cytokines, small bowel resection and the resultant calcium and vitamin D deficiencies, hypogonadism, malnutrition and the cachexia of inflammation all play a role. However, the mechanism responsible for osteoporosis associated with CD remains unclear. Treatment of decreased bone density in CD patients has been limited to calcium and vitamin D replacement. The present understanding of the pathophysiology, mechanism and treatment of osteoporosis in CD is reviewed, with the focus on the role of steroid-induced osteoporosis and the use of bisphosphonates.


Sign in / Sign up

Export Citation Format

Share Document